Related Experiment Videos
Apolipoprotein E genotypes in Parkinson's disease with and without dementia
W C Koller1, S L Glatt, J P Hubble
1Department of Neurology, University of Kansas Medical Center, Kansas City 66160-7314.
Annals of Neurology
|February 1, 1995
Summary
The apolipoprotein E (Apo E) epsilon 4 allele does not influence Parkinson's disease development or associated dementia. Apo E genotype frequencies were similar in patients with and without dementia compared to controls.
Area of Science:
- Neurogenetics
- Neurology
Background:
- The apolipoprotein E (Apo E) epsilon 4 allele is a known genetic risk factor for Alzheimer's disease.
- Parkinson's disease (PD) shares clinical and pathological characteristics with Alzheimer's disease (AD).
Purpose of the Study:
- To investigate the association between Apo E genotypes and the presence of dementia in Parkinson's disease patients.
- To determine if Apo E epsilon 4 allele influences Parkinson's disease development or dementia.
Main Methods:
- Genotyping for Apo E alleles in 52 PD patients with dementia and 61 PD patients without dementia.
- Cognitive status assessed using National Institute of Neurological and Communicative Disorders and Stroke criteria and Mattis Dementia Rating Scale (DRS).
- Comparison of genotype and allele frequencies with 78 healthy controls.
Main Results:
- No significant differences in Apo E genotype or allele frequencies were observed between demented and nondemented PD patients.
- Apo E genotype and allele frequencies in PD patients did not differ from the control group.
- The Apo E epsilon 4 allele was not found to be a risk factor for PD or PD-associated dementia.
Conclusions:
- The Apo E epsilon 4 allele does not appear to influence the development of Parkinson's disease.
- The Apo E epsilon 4 allele is not associated with the incidence or progression of dementia in Parkinson's disease patients.